(UroToday.com) The second session of the 7th Annual AIBCCR Symposium, chaired by Dr. Bishoy Faltas (Weill Cornell Medicine) provided a comprehensive overview of emerging data on germline variants in urothelial cancer (UC).
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s non-prostate cancer session included a presentation by Dr. Yann Vano discussing the CABIR study of patients receiving cabozantinib-nivolumab versus nivolumab-cabozantinib after receiving a prior VEGFR TKI for metastatic clear cell RCC. Nivolumab and cabozantinib are two approved agents after a prior TKI in […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s prostate cancer session included a presentation by Dr. Daniel George presenting data assessing real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC). ADT remains the backbone of therapy for mCSPC, however randomized trials have shown […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s non-prostate cancer session included a presentation by Dr. Toni Choueiri discussing outcomes of subgroup analyses and a toxicity update among patients in the phase 3 CLEAR trial for advanced renal cell carcinoma (RCC). In the CLEAR trial, lenvatinib + pembrolizumab demonstrated significant improvement in […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s prostate cancer session included a presentation by Dr. Nobuaki Matsubara estimating overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study.1
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s non-prostate cancer session included a presentation by Dr. Brian Rini discussing a new 3-arm phase 3 trial concept and design, which will randomize patients with advanced clear cell RCC in the first-line setting to either pembrolizumab + belzutifan + lenvatinib versus MK-1308A + […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s prostate cancer session included a presentation by Dr. Evan Yu discussing updated follow-up of the KEYNOTE-365 Cohort A trial. Data from the phase I/II KEYNOTE-365 study previously showed antitumor activity and acceptable safety of pembrolizumab + olaparib in patients with molecularly unselected, docetaxel-pretreated mCRPC enrolled […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s prostate cancer session included a presentation by Dr. Johann de Bono presenting data assessing the impact of circulating tumor cell (CTC) morphologic sub-types prior to treatment in the CARD trial.1 In the CARD study (NCT02485691), cabazitaxel significantly improved radiographic progression-free survival (rPFS) and overall […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s prostate cancer session included a presentation by Dr. Peter Goebell discussing real-world treatment patterns among patients with metastatic hormone-sensitive prostate cancer (mHSPC).
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 virtual annual meeting’s non-prostate cancer session included a presentation by Dr. Robert Motzer discussing updated data from the CheckMate 214 trial with 5-years of follow-up. The combination of nivolumab + ipilimumab is approved by the European Commission and the US FDA for first-line treatment of patients with […]
